Sinotherapeutics Inc., a specialty pharmaceutical company, develops generic and formulation products in China. It offers posaconazole delayed-release tablets, ursodeoxycholic acid capsules, bupropion hydrochloride extended-release tablets, paroxetine extended-release tablets, sevelamer carbonate tablets, and propafenone hydrochloride extended-release capsules. The company provides CRO/CDMO services including pre-formulation study, formulation and process development, clinical sample manufacturing, NDA registration batch manufacturing, quality standard establishment, and regulatory dossier document preparation and submission. Sinotherapeutics Inc. was founded in 2012 and is headquartered in Shanghai, China.
Stock data | 2024 | Change |
---|---|---|
Price | $1.49 | N/A |
Market Cap | $676.35M | N/A |
Shares Outstanding | 453.34M | N/A |
Employees | 248.00 | N/A |